APA (7th ed.) Citation

Mol, I., Hu, Y., LeBlanc, T. W., Cappelleri, J. C., Chu, H., Nador, G., . . . Hlavacek, P. Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: An updated matching-adjusted indirect comparison. Becaris Publishing Limited.

Chicago Style (17th ed.) Citation

Mol, Isha, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, and Patrick Hlavacek. Elranatamab Versus Physician’s Choice of Treatment in Patients with Triple-class Exposed/refractory Multiple Myeloma: An Updated Matching-adjusted Indirect Comparison. Becaris Publishing Limited.

MLA (9th ed.) Citation

Mol, Isha, et al. Elranatamab Versus Physician’s Choice of Treatment in Patients with Triple-class Exposed/refractory Multiple Myeloma: An Updated Matching-adjusted Indirect Comparison. Becaris Publishing Limited.